The Clinical Significance of Acid Rebound in Functional Dyspepsia

Status Terminated

Clinical Trial Summary

Proton pump inhibitors (PPI) have been shown to cause acid reflux related symptoms at withdrawal in healthy volunteers, a phenomenon known as Rebound Acid Hyper Secretion. Whether this also applies for patients with dyspeptic symptoms but without true reflux disease (functional dyspepsia) treated with PPI is unknown. If this is the case, it could lead to an unfortunate long term use of PPI, since the acid rebound renders withdrawal too difficult.

This is a single centre, randomized, double-blinded, placebo-controlled cross over study. Study period is 12 weeks per study subject. Study subjects are referred to the study from General Practitioner (GP) and the gastroenterology department or endoscopy clinic of the investigational centre.

The study population consists of patients who seek their GP because of dyspepsia without alert signs, and whom the GP may consider starting on PPI. Out patients referred to the gastroenterology department or endoscopy clinic of the investigational centre because of dyspepsia without specific exclusion criteria are also invited to participate.

Baseline interview, upper endoscopy and pH monitoring are performed one week before inclusion to exclude patients with GERD. Helicobacter Pylori (Hp.) status is assessed by Helicobacter Urease Test (HUT). Hp. positive subjects without ulcus are not excluded.

Patients with a positive pH monitoring will not be included in the analysis regarding the primary endpoint (Development of GERD) but will be included in the analysis regarding one of the secondary endpoints (Effect of PPI on Functional Dyspepsia).

Study subjects are randomized to either pantoprazol followed by cross over to placebo or to placebo. Escape medication in the form of Gaviscon can be used on demand.

Internet based questionnaires are answered weekly. Questionnaires consist of the Gastrointestinal Symptom rating Scale (GSRS) in combination with items assessing postprandial fullness and items assessing the Montreal Criteria for Gastro Esophageal Reflux Disease (GERD).

Compliance to protocol is assessed at hospital visits every fourth week. At the end of study endoscopy and pH monitoring are repeated.

Clinical Trial Description

n/a

Study Design

Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment

Related Conditions & MeSH terms

Clinical Trial Details

NCT number	NCT01373970
Study type	Interventional
Source	University Hospital Koge
Contact
Status	Terminated
Phase	Phase 4
Start date	May 2011
Completion date	September 2013

View Details

See also
Status	Clinical Trial	Phase
Completed	`NCT04656730` - Effect of STW5 (Iberogast ®) and STW5-II (Iberogast N®) on Transit and Tolerance of Intestinal Gas	Phase 4
Completed	`NCT04464369` - Functional Dyspepsia: Validation of the Leuven Postprandial Distress Scale (LPDS) in a Placebo-controlled Trial	Phase 4
Completed	`NCT01671670` - Acupuncture for Patients With Function Dyspepsia	Phase 2/Phase 3
Completed	`NCT00987805` - Efficacy of Banhasasim-tang on Functional Dyspepsia	Phase 4
Completed	`NCT00761358` - To Verify the Efficacy of Z-338 in Subjects With Functional Dyspepsia	Phase 3
Completed	`NCT00693407` - Study of Endogenous Inhibitory Modulation During Gastric and Somatic Stimulation	N/A
Recruiting	`NCT01240096` - Mirtazapine Versus Placebo in Functional Dyspepsia	Phase 4
Recruiting	`NCT04540549` - Effects of Exercise on Functional Dyspepsia Based on Rome IV	N/A
Recruiting	`NCT03652571` - Nortriptyline for the Treatment of Functional Dyspepsia	Phase 3
Recruiting	`NCT06068114` - Gastric Pathophysiology in Diabetes
Recruiting	`NCT03825692` - International Clinical Study of Zhizhu Kuanzhong Capsule	Phase 4
Not yet recruiting	`NCT04548011` - Acupuncture of Different Treatment Frequency on Improving Quality of Life in Patients With Functional Dyspepsia	N/A
Terminated	`NCT02567578` - A Trial to Evaluate the Efficacy and Safety of YH12852 in Patients With Functional Dyspepsia	Phase 2
Completed	`NCT03007433` - Assessment of GI Function to a Large Test Meal by Non-invasive Imaging	N/A
Active, not recruiting	`NCT00990405` - Clinical Study to Evaluate the Efficacy and the Safety of Eradication Therapy for Helicobacter Pylori in Functional Dyspepsia	Phase 4
Completed	`NCT00404534` - Helicobacter Eradication Relief of Dyspeptic Symptoms	Phase 3
Completed	`NCT03043625` - Visceral Manipulation Treatment to Patients With Non-specific Neck Pain With Functional Dyspepsia	N/A
Completed	`NCT03225248` - Efficacy and Safety of UI05MSP015CT in Functional Dyspepsia	Phase 3
Recruiting	`NCT05587127` - Exposure-Based CBT for Avoidant/Restrictive Food Intake in Functional Dyspepsia	N/A
Recruiting	`NCT01021475` - Does Visceral Manipulation Works in Treating Functional Dyspepsia?	Phase 1

Clinical trials are conducted in a series of steps, called phases - each phase is designed to answer a separate research question.

Phase 1: Researchers test a new drug or treatment in a small group of people for the first time to evaluate its safety, determine a safe dosage range, and identify side effects.
Phase 2: The drug or treatment is given to a larger group of people to see if it is effective and to further evaluate its safety.
Phase 3: The drug or treatment is given to large groups of people to confirm its effectiveness, monitor side effects, compare it to commonly used treatments, and collect information that will allow the drug or treatment to be used safely.
Phase 4: Studies are done after the drug or treatment has been marketed to gather information on the drug's effect in various populations and any side effects associated with long-term use.

The Clinical Significance of Acid Rebound in Functional Dyspepsia — CLARIFY

Clinical Trial Summary

Clinical Trial Description

Study Design

Related Conditions & MeSH terms